bioRxiv Science⌕ Search

Biology subjects

Chimal-Juarez, E.

Publications and source records attributed to Chimal-Juarez, E..

2 recordsLinked to original sources

Tau Ablation Rewires Brain Cell Programs in Health and Restores Function in Disease

Tau is a microtubule-associated protein with diverse roles in the healthy brain but contributes to neurodegenerative disorders when dysregulated. Although tau ablation has shown protective effects in several disease models, how its absence confers this protection remain unclear. Here, we performed and analyzed single-nucleus RNA sequencing on cortices of aged tau knockout (Mapt-/-) mice in a wild type background as well as in a vascular amyloid model to evaluate the effect on disease context. Comparisons in a wild type setting revealed that tau ablation induced compensatory remodeling across multiple cell types. Excitatory neurons expanded into a distinct subtype with unique glutamatergic signaling, astrocytes adopted synaptoprotective states, oligodendrocytes upregulated genes supporting connectivity and plasticity, and microglia engaged structural remodeling programs. In contrast, in disease, tau removal not only restored functions disrupted by vascular amyloid pathology, but also generated new phenotypes. Excitatory neurons rewired receptor and postsynaptic signaling, astrocytes and oligodendrocytes recovered wild-type-like gene programs related to neurotransmitter cycling, synaptic support, and myelin integrity, and microglia reprogrammed toward sensing and mounting responses. Together, these findings demonstrate that tau ablation reshapes brain cellular programs in a context-dependent manner, exerting adaptive responses in the otherwise healthy brain while restoring homeostatic functions under vascular amyloid pathology. These results position tau as a key regulator of neuronal-glial network balance and highlight the importance of understanding how tau influences distinct cellular programs within specific disease environments.

neuroscience↗

Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders

BackgroundSynucleinopathies, including Parkinsons disease, multiple system atrophy, and dementia with Lewy bodies, are neurodegenerative disorders caused by the accumulation of misfolded alpha-synuclein protein. Developing effective vaccines against synucleinopathies has been challenging due to the difficulty of stimulating an immune-specific response against alpha-synuclein, conferring neuroprotection without causing harmful autoimmune reactions, and selectively targeting only pathological forms of alpha-synuclein. Previous attempts using linear peptides and epitopes without control of the antigen structure for immunization failed in clinical trials. The immune system was unable to distinguish between the native alpha-synuclein and its amyloid form. ResultsThe prion domain of the fungal HET-s protein was selected as a scaffold to introduce select epitopes from the surface of alpha-synuclein fibrils. Four vaccine candidates were generated by introducing specific amino acid substitutions onto the surface of the scaffold protein in regions that showed structural similarity to alpha-synuclein fibril structures. Each vaccine candidate had unique amino acid substitutions that imitated a specific epitope from alpha-synuclein amyloid fibrils. The approach successfully mimicked the stacking of the parallel in-register beta-sheet structure seen in alpha-synuclein fibrils as the vaccine candidates were found to be structurally stable and self-assembling into the desired conformations. All vaccine candidates induced substantial levels of IgG antibodies that recognized pathological alpha-synuclein fibrils derived from a synucleinopathy mouse model. Furthermore, the resulting anti-sera recognized pathological alpha-synuclein aggregates in brain lysates from patients who died from dementia with Lewy bodies, multiple system atrophy, or Parkinsons disease, but did not recognize linear alpha-synuclein peptides. Each vaccine candidate induced a unique pattern of reactivity toward alpha-synuclein aggregates contained in distinct disease pathologies. ConclusionsThis new approach, based on the rational design of vaccines using the secondary and tertiary structure of alpha-synuclein amyloid fibrils and strict control over the exposed antigen structure used for immunization, as well as the ability to mimic aggregated alpha-synuclein, provides a promising avenue towards developing effective vaccines against alpha-synuclein fibrils, which may be crucial for the prevention and treatment of synucleinopathies.

biochemistry↗